image description

Alexander N. Gross

Associate

Alexander N. Gross

Associate
New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588
[email protected]
Alexander Gross is a member of the Firm’s Litigation Group. His practice includes a broad range of litigation matters in a variety of venues, with an emphasis on intellectual property, technology, antitrust, and complex commercial disputes. He has significant trial experience, including cross-examining an expert at trial and successfully arguing evidentiary motions and motions to exclude expert testimony. He also has appellate experience, representing clients in appeals to the Second and Fifth Circuits. He has also represented clients in inquiries by the Department of Justice, the Securities and Exchange Commission, the Commodity Futures Trading Commission, and the New York Department of Financial Services.
 
Mr. Gross’s pro bono practice includes achieving a successful resolution for a client in New York State housing court and representing clients in criminal matters in the Eastern District of New York.

SELECTED REPRESENTATIONS

Intellectual Property
  • Ocado Group as trial counsel in successful defense of ITC Section 337 investigation based on allegations of infringement of five patents in which the judge ruled in Ocado’s favor on all claims and patents, finding three patents invalid and one not infringed (the fifth patent was withdrawn the day before trial).
  • Columbia University as trial counsel securing a unanimous verdict in its favor in a two-week patent infringement jury trial against NortonLifeLock in the Eastern District of Virginia.
  • BlackBerry Limited as hearing counsel in successful pursuit of its $1 billion patent license claim against Qualcomm Incorporated in a JAMS arbitration seated in California.

Antitrust
  • Bayer AG in connection with successful global antitrust clearance of Bayer’s $66 billion acquisition of Monsanto Company, including post-clearance audits by a monitoring trustee.
  • Novartis in connection with its $9.7 billion acquisition of The Medicines Company.